Souhaitez-vous accéder aux communiqués récents ?

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July...

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering...

Exton, PA, July 08, 2026 (GLOBE NEWSWIRE) -- The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease...

Tekton Research, a multi-specialty clinical research site organization, is expanding its partnership with Summit Clinical Research Solutions (“Summit”).

Couverture et futur remboursement sécurisés pour NASHnext®, le test diagnostique sanguin non invasif développé par Labcorp, basé sur la technologie propriétaire NIS4® de GENFITUn ciblage sur les...

GENFIT announced the coverage and future reimbursement by U.S. Medicare for NASHnext®, a non invasive blood test available through Labcorp

Labcorp OnDemand facilite l’accès au test NASHnext® dans le cadre d’un parcours de soins piloté par un médecin, pour identifier les patients atteints de MASH « à risque » Cette plateforme élargit...

Access to Labcorp’s NASHnext® is now available through Labcorp OnDemand

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel...

Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH Rezdiffra improved atherogenic lipid profiles...